University of Edinburgh at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
University of Edinburgh brings 5 presentations to ESGCT 2026 in Hamburg. Its work centres on gene therapy for neurological disorders, including self-regulating designs for Rett syndrome and both myeloid and stem cell routes to the childhood disorder MPS IIIA. A second strand compares how regulated therapies behave in the brain.
| Organization | ESGCT 2026 Attendance |
|---|---|
University of Edinburgh Edinburgh, UK | |
Scottish research university with groups developing gene therapy for neurological disorders such as Rett syndrome. | Talk Wed Oct 28 11:00am–12:30pm Self-regulating gene therapy for Rett syndrome Rare and inherited disease Poster Wed Oct 28 1:30pm–3:30pm An iPSC-based neural gene therapy approach for MPS IIIA disease Poster Wed Oct 28 1:30pm–3:30pm Developing a myeloid-based gene therapy for the treatment of MPS IIIA Poster Wed Oct 28 1:30pm–3:30pm Evaluating heparan sulfate binding peptides (HS5) fused to Iduronate-2-Sulfatase, compared with ApoEII peptides for the treatment of mucopolysaccharidosis type II in mice. Poster Wed Oct 28 1:30pm–3:30pm Myth versus measurement: direct CNS comparison of two miRNA based regulated gene therapies in a mosaic model of Rett syndrome |
Instantly find 20 buyers from University of Edinburgh
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction